AstraZeneca Says Drug Cocktail Effective Against COVID-19 in Late-Stage Study
The phase 3 trial preliminary results showed the drug cut the risk of developing severe COVID-19 or dying by 50 percent compared to a placebo in people who did not require hospitalization and had been showing symptoms for a week or less.
The phase 3 trial preliminary results showed the drug, a long acting antibody (LAAB) combination, cut the risk of developing severe COVID-19 or dying by 50 percent compared to a placebo in people who did not require hospitalization and had been showing symptoms for a week or less.
The drug, AZD7442, was even more effective when given within five days of symptom onset, according to AstraZeneca.
“These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic,” Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, said in a statement.
Early trial results were based on an analysis of 822 participants. The trial included 903 participants, about half of whom were given a placebo. The full results will be submitted to a peer-reviewed medical journal and presented at an unspecified upcoming meeting, the company said.
The statement continued the trend of companies releasing summaries of trial results well before the full data are available, a trend that has frustrated some experts.
“It’s unfortunately been a common pathway throughout the pandemic,” Dr. Michael Carome, director of Public Citizen’s Health Research Group, told The Epoch Times.
The drug does appear to significantly reduce the chances of a COVID-19 patient needing hospital care but, as is the case with Merck’s antiviral, not much data on the drug’s safety was released, Carome said.
“As so often the case with these press releases, they sort of focus on the potential benefits and downplay or exclude important information about understanding the risk of adverse events. And so, eventually, that information will be submitted to the FDA and will come out but right now we don’t have that data,” he added.
Merck announced Monday it was seeking emergency use authorization from the Food and Drug Administration (FDA) for its drug, which is in a pill form and requires a five-day course.
AstraZeneca last week submitted documents to the drug regulator for its LAAB, but only for prophylactic, or preventative, use.
The new trial data was shared with the FDA, the company said.
If authorized, the drugs from Merck and AstraZeneca would be added to a growing number of COVID-19 treatments, including remdesivir and monoclonal antibodies from Eli Lilly, GlaxoSmithKline, and Regeneron.
“I think in general these are helpful and are giving us more arrows in the quiver,” Dr. Roger Klein, who has advised U.S. government agencies like the Food and Drug Administration and currently works as a policy adviser to the Heartland Institute, told The Epoch Times.
“It will be helpful to see the primary data” from the Merck and AstraZeneca trials, he added.
By Zachary Stieber
Zachary Stieber covers U.S. news, including politics and court cases. He started at The Epoch Times as a New York City metro reporter.
The Epoch Times is the fastest-growing independent news media in America. We are nonpartisan and dedicated to truthful reporting.
We are free from the influence of any government, corporation, or political party—this is what makes us different from other media organizations. Our goal is to bring our readers accurate information so they can form their own opinions about the most significant topics of our time.
We don’t follow the unhealthy trend of agenda-driven journalism prevalent in today’s media environment. Instead, we use our principles of Truth and Tradition as our guiding light. We highlight in our reporting the best of humanity, the valuable lessons of history, and traditions that are beneficial for society.
The Epoch Times was founded in the United States in the year 2000 in response to communist repression and censorship in China. Our founders, Chinese-Americans who themselves had fled communism, sought to create an independent media to bring the world uncensored and truthful information.
The Epoch Times has received numerous awards for our reporting and design, including from the New York Press Association, the Society of Professional Journalists, and the Society for News Design.
The Epoch Times’ media network currently covers 21 languages and 33 countries.